Literature DB >> 20410185

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Fiona M Ross1, Laura Chiecchio, GianPaolo Dagrada, Rebecca K M Protheroe, David M Stockley, Christine J Harrison, Nicholas C P Cross, Alex J Szubert, Mark T Drayson, Gareth J Morgan.   

Abstract

A large series of plasma cell dyscrasias (n=2207) was examined for translocations which deregulate the MAF genes, t(14;20)(q32;q12) and t(14;16)(q32;q23), and their disease behavior was compared to a group characterized by the t(4;14)(p16;q32) where CCND2 is also up-regulated. The t(14;20) showed low prevalence in myeloma (27/1830, 1.5%) and smoldering myeloma (1/148, <1%) with a higher incidence in MGUS (9/193, 5% P=0.005). Strong associations with del(13) (76%), non-hyperdiploidy (83%) and gain of 1q (58%) were seen but no association with an IgA M-protein or absence of bone disease was noted. All three translocations were associated with poor outcome in myeloma, but strikingly all t(14;20) MGUS/smoldering myeloma cases (n=10) had stable, low level disease. In contrast, the 10 t(14;16) and 25 t(4;14) MGUS/smoldering myeloma cases were associated with both evolving and non-evolving disease. None of the associated genetic abnormalities helped to predict for progression from MGUS or smoldering myeloma.

Entities:  

Mesh:

Year:  2010        PMID: 20410185      PMCID: PMC2895050          DOI: 10.3324/haematol.2009.016329

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 2.  Multiple myeloma: evolving genetic events and host interactions.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

3.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

4.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.

Authors:  U Malgeri; L Baldini; V Perfetti; S Fabris; M C Vignarelli; G Colombo; V Lotti; S Compasso; S Bogni; L Lombardi; A T Maiolo; A Neri
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

5.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Authors:  Hervé Avet-Loiseau; Thierry Facon; Bernard Grosbois; Florence Magrangeas; Marie-José Rapp; Jean-Luc Harousseau; Stéphane Minvielle; Régis Bataille
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Genomic abnormalities in monoclonal gammopathy of undetermined significance.

Authors:  Rafael Fonseca; Richard J Bailey; Gregory J Ahmann; S Vincent Rajkumar; James D Hoyer; John A Lust; Robert A Kyle; Morie A Gertz; Philip R Greipp; Gordon W Dewald
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 8.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

Authors:  Brian G M Durie; Robert A Kyle; Andrew Belch; William Bensinger; Joan Blade; Mario Boccadoro; J Anthony Child; Raymond Comenzo; Ben Djulbegovic; Dorotea Fantl; Gosta Gahrton; Jean Luc Harousseau; Vania Hungria; Douglas Joshua; Heinz Ludwig; Jayesh Mehta; Angelina Rodrique Morales; Gareth Morgan; Amara Nouel; Martin Oken; Raymond Powles; David Roodman; Jesus San Miguel; Kazuyuki Shimizu; Seema Singhal; Bhawna Sirohi; Pieter Sonneveld; Guido Tricot; Brian Van Ness
Journal:  Hematol J       Date:  2003

9.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Authors:  Elaine M Hurt; Adrian Wiestner; Andreas Rosenwald; A L Shaffer; Elias Campo; Tom Grogan; P Leif Bergsagel; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2004-02       Impact factor: 31.743

10.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  29 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

Review 3.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 4.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

Review 5.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

6.  Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

Authors:  Susanna J Jacobus; Shaji Kumar; Hajime Uno; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Michael E Williams; David S Siegel; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

Review 7.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

Review 8.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

9.  Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.

Authors:  Simona Caltagirone; Marina Ruggeri; Simona Aschero; Milena Gilestro; Daniela Oddolo; Francesca Gay; Sara Bringhen; Caterina Musolino; Luca Baldini; Pellegrino Musto; Maria T Petrucci; Gianluca Gaidano; Roberto Passera; Benedetto Bruno; Antonio Palumbo; Mario Boccadoro; Paola Omedè
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

Review 10.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.